Pancreatic Cancer Research

ResearcherTufts UniversityNo recent work listed

Konstantinos Nikolaos Syrigos

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3474-1363; OpenAlex author ID A5049509860, A5106524954, A5108076478. Sources: OpenAlex.

Their work

Papers
17 (first author 13, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
14
Papers, trials and grants by year

2011: 3 papers · 2012: 2 papers · 2013: 6 papers · 2014: 4 papers · 2015: 1 paper · 2016: 1 paper

Papers 17

  1. Immunotherapy for pancreatic cancer. Last author DOI 10.1007/s00432-016-2119-2↗
  2. Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go? Last author DOI 10.4251/wjgo.v7.i10.172↗
  3. The role of biliary drainage in patients with pancreatic adenocarcinoma. First author DOI 10.6092/1590-8577/2292↗
  4. Pancreatic cancer in 2014. First author DOI 10.6092/1590-8577/2403↗
  5. Risk determination for pancreatic cancer. First author DOI 10.6092/1590-8577/2591↗
  6. Pharmacogenetics in pancreatic cancer. Co-author DOI 10.6092/1590-8577/2689↗
  7. Second-line therapy in pancreatic cancer. First author DOI 10.6092/1590-8577/1463↗
  8. Pancreatic cancer: updates on translational research and future applications. First author DOI 10.6092/1590-8577/1466↗
  9. Locally advanced pancreatic cancer. Co-author DOI 10.6092/1590-8577/1469↗
  10. Novel agents in the treatment of pancreatic adenocarcinoma. First author DOI 10.6092/1590-8577/1474↗
  11. Preclinical research in treatment of pancreatic cancer. First author DOI 10.6092/1590-8577/1643↗
  12. Prognostic factors in pancreatic cancer. First author DOI 10.6092/1590-8577/1644↗
  13. Desmoplasia in pancreatic cancer. Can we fight it? First author DOI 10.1155/2012/781765↗
  14. Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. First author DOI 10.1177/1758834012446008↗
  15. Treatment for refractory pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. First author PMID 21386632↗
  16. Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco… First author PMID 21386633↗
  17. Translational research in pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. First author PMID 21386635↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Muhammad Wasif Saif · 17 shared papers, 2011–2016 · strength 1.04
  2. Anastasios Dimou · 3 shared papers, 2011–2013 · strength 0.16
  3. Maria I Toki · 2 shared papers, 2014 · strength 0.14
  4. Evangelia V. Skoura · 2 shared papers, 2013 · strength 0.12
  5. Georgios Oikonomopoulos · 2 shared papers, 2013 · strength 0.11
  6. Elias Alexandros Kotteas · 1 shared paper, 2016 · strength 0.10
  7. Dimitra Grapsa · 1 shared paper, 2015 · strength 0.08
  8. Serafim Kaltsas · 1 shared paper, 2014 · strength 0.07
  9. Ioannis Tourkantonis · 1 shared paper, 2014 · strength 0.06
  10. Evangelos Sarris · 1 shared paper, 2013 · strength 0.06
  11. Kathryn E. Huber · 1 shared paper, 2013 · strength 0.05
  12. Eirini Merika · 1 shared paper, 2012 · strength 0.05
  13. Nektaria Makrilia · 1 shared paper, 2011 · strength 0.04
  14. Alexios S Strimpakos · 1 shared paper, 2011 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.